Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Fund listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
Nontuberculous Mycobacterium - Medicare Access (Medicare patients only)
Status
ClosedThis fund is temporarily closed to new patients due to lack of sufficient funding. Please continue to visit our Disease Funds page often, as replenished funds reopen as quickly as possible. If you currently have a grant with HealthWell, your grant will remain active for the entire 12 month grant cycle or until you have exhausted your allocated grant amount, whichever comes first. You can continue to use your pharmacy card or submit requests for reimbursements during your designated grant cycle.
Fund Type
CopayPremium (Medicare Part B only)
Maximum Award Level
Pharmacy Card Fund
YesMinimum Copay Reimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium Reimbursement Amount
Household Income Limit
400% of the Federal Poverty Level(adjusted for household size and high cost of living areas)
Treatments Covered
- Amikacin
- Amikacin Intravenous
- Arikayce
- Avelox
- Azasite
- Cetraxal
- Cipro
- Ciprofloxacin
- Clarithromycin
- Clofazimine
- Coly-mycin M
- Cycloserine
- Doxycycline
- Erythromycin
- Ethambutol
- Floxin
- Gatifloxacin
- Isoniazid
- Moxeza
- Moxyfloxacin
- Myambutol
- Mycobutin
- Nuzyra
- Ocuflox
- Ofloxacin
- Priftin
- Rifabutin
- Rifadin
- Rifampin
- Rifapentine
- Sirturo
- Streptomycin
- Tigecycline
- Tygacil
- Vigamox
- Zithromax
- Zymaxid
Fund Definition
Assistance with the prescription drugs and biologics used in the treatment of nontuberculous mycobacteria.
Grant Utilization
As a result of the impact of the Inflation Reduction Act on Medicare Part D maximum out of pocket, average grant utilization calculation for Medicare Access Funds are based on forecasted utilization. The forecasted average grant utilization for this disease fund is: $1,030Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
-
This is a Medicare Access Fund. In order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without Medicare to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Nontuberculous Mycobacterium (NTM)
Nontuberculous mycobacterium (NTM) are naturally-occurring organisms (germs) found in water and soil. While most species of NTM do not cause human disease, except in people with weak lungs or immune systems, people who are susceptible inhale the organisms from misty water or from the soil, which lead to lung infections, according to the Chest Foundation. These lung infections become slowly progressive, which can destroy lung tissue and lead to other, more serious lung conditions. Between 12 and 18 thousand new cases of NTM lung infections are diagnosed each year in the United States. Source: Chest Foundation
Additional Educational Resources
You may also visit our Resource List to view other copayment organizations that may provide assistance.
